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Introduction
Adults receiving antiretroviral therapy (ART) and ageing 
with HIV have a greater burden of chronic non-
communicable diseases than do adults without HIV.1 The 
increased risk is hypothesised to be the result of a 
combination of factors, such as the increased prevalence 
of traditional risk factors for non-communicable diseases 
in adults with HIV;2,3 the possible synergistic effect of viral 
coinfection, particularly with hepatitis C virus;4 HIV-
associated immunosuppression, immune activation, 
inflammation, and hypercoaguability5 (which is blunted 
but not normalised with ART);6 and ART drugs, including 
previous exposure to first-generation nucleoside analogue 
reverse transcriptase inhibitors and protease inhibitors.7 
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Summary
Background Adults with HIV have an increased burden of non-AIDS-defining cancers, myocardial infarction, end-stage 
liver disease, and end-stage renal disease. The objective of this study was to estimate the population attributable fractions 
(PAFs) of preventable or modifiable HIV-related and traditional risk factors for non-AIDS-defining cancers, myocardial 
infarction, end-stage liver disease, and end-stage renal disease outcomes.
Methods We included participants receiving care in academic and community-based outpatient HIV clinical cohorts in 
the USA and Canada from Jan 1, 2000, to Dec 31, 2014, who contributed to the North American AIDS Cohort Collaboration 
on Research and Design and who had validated non-AIDS-defining c ancers, m yocardial i nfarction, e nd-stage l iver 
disease, or end-stage renal disease outcomes. Traditional risk factors were tobacco smoking, hypertension, elevated total 
cholesterol, type 2 diabetes, renal impairment (stage 4 chronic kidney disease), and hepatitis C virus and hepatitis B virus 
infections. HIV-related risk factors were low CD4 count (<200 cells per µL), detectable plasma HIV RNA (>400 copies 
per mL), and history of a clinical AIDS diagnosis. PAFs and 95% CIs were estimated to quantify the proportion of 
outcomes that could be avoided if the risk factor was prevented.
Findings In each of the study populations for the four outcomes (1405 of 61 500 had non-AIDS-defining cancer, 347 of 
29 515 had myocardial infarctions, 387 of 35 044 had end-stage liver disease events, and 255 of 35 620 had end-stage renal 
disease events), about 17% were older than 50 years at study entry, about 50% were non-white, and about 80% were men. 
Preventing smoking would avoid 24% (95% CI 13–35) of these cancers and 37% (7–66) of the myocardial infarctions. 
Preventing elevated total cholesterol and hypertension would avoid the greatest proportion of myocardial infarctions: 
44% (30–58) for cholesterol and 42% (28–56) for hypertension. For liver disease, the PAF was greatest for hepatitis C 
infection (33%; 95% CI 17–48). For renal disease, the PAF was greatest for hypertension (39%; 26–51) followed by 
elevated total cholesterol (22%; 13–31), detectable HIV RNA (19; 9–31), and low CD4 cell count (13%; 4–21).
Interpretation The substantial proportion of non-AIDS-defining cancers, myocardial infarction, end-stage liver disease, 
and end-stage renal disease outcomes that could be prevented with interventions on traditional risk factors elevates the 
importance of screening for these risk factors, improving the effectiveness of prevention (or modification) of these risk 
factors, and creating sustainable care models to implement such interventions during the decades of life of adults living 
with HIV who are receiving care.
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Although some specific antiretroviral drugs have been 
associated with an increased risk for some non-
communicable diseases, initiation of ART at higher 
CD4 cell counts results in a decreased risk of cancer in 
adults ageing with HIV, demonstrating the potential 
importance of early ART initiation for prevention of 
non-communicable diseases.8 Despite known roles of 
traditional and HIV-related risk factors in the development 
of non-communicable diseases among adults with HIV, 
how much of the burden can be attributed to each of 
these factors is unknown.
Over the past two decades, cancer, cardiovascular 
disease, and liver disease have become the top causes of 
non-AIDS-related death among adults with HIV.9,10 End-
stage liver disease is also responsible for substantial 
morbidity among adults with HIV because of the high 
prevalence of chronic hepatitis B and hepatitis C infection 
in this population.11–13 Although rare, end-stage renal 
disease is more common among people with HIV than 
among the general population14 and has been hypothesised 
to increase as a result of the combined effect of nephrotoxic 
ART regimens and age-associated declines in renal 
function.15
Our goal was to estimate the proportion of non-AIDS-
defining cancers, myocardial infarction, end-stage liver 
disease, and end-stage renal disease events that can be 
attributed to traditional and HIV-related risk factors 
among adults with HIV who have been successfully 
linked into care. To this end, we analysed traditional and 
HIV-related risk factors for these four validated non-
communicable disease outcomes among participants 
of the North American AIDS Cohort Collaboration 
on Research and Design (NA-ACCORD). We used a 
population attributable fraction (PAF) approach to 
quantify the proportion of non-communicable diseases 
that could be eliminated if particular risk factors were 
not present, and can be used to inform prioritisation of 
interventions aimed at reducing risk factor exposure to 
preserve the health of adults with HIV.
Methods
Study design and participants
The NA-ACCORD is the largest consortium of HIV 
cohorts in the USA and Canada and is the North American 
region of the International Epidemiologic Databases to 
Evaluate AIDS (IeDEA) project, supported by the National 
Institutes of Health. Details on this collaboration have 
been published previously.16 Briefly, the NA-ACCORD 
consists of single-site and multisite clinical and interval 
cohorts in various settings, ranging from community 
health centres to academic institutions. The cohorts have 
prospectively collected data on over 180 000 adults 
(≥18 years) with HIV who had at least two care visits 
within 12 months from more than 200 sites in the USA 
and Canada. Each cohort submits comprehensive data on 
enrolled participants to the Data Management Core 
(University of Washington, Seattle, WA, USA), where the 
data undergo quality control, are harmonised across 
cohorts, and are transmitted to the Epidemiology/
Biostatistics Core (Johns Hopkins University, Baltimore, 
MD, USA), which did the analyses presented in this 
Article.
Participants from clinical cohorts within the 
NA-ACCORD with complete access to both inpatient and 
outpatient electronic medical records that validated the 
occurrences of non-AIDS-defining cancers, myocardial 
infarction, end-stage renal disease, and end-state liver 
disease were eligible for inclusion in the analyses presented 
in this Article.
The human-participant research activities of the 
NA-ACCORD and each of the participating cohort studies 
have been reviewed and approved by their respective local 
institutional review boards and the Johns Hopkins School 
of Medicine. The Johns Hopkins Bloomberg School of 
Research in context
Evidence before this study
We searched PubMed with the terms “HIV and cancer”, “HIV and 
myocardial infarction”, “HIV and end stage liver disease”, and 
“HIV and end stage renal disease” for articles published in 
English up to Jan 12, 2018. Studies have shown there is an 
increased burden of non-AIDS defining cancers, myocardial 
infarction, end-stage renal disease, and end-stage liver disease 
among adults ageing with HIV compared with those without 
HIV. Although both traditional and HIV-related risk factors have 
been associated with these outcomes, the proportion of 
outcomes attributed to traditional and HIV-related risk factors 
can help guide programmes and policies for interventions.
Added value of this study
To our knowledge, this is the first study to estimate 
population-attributable fractions for four age-related 
conditions in a large study population of adults with HIV. Risk 
factors were grouped as traditional or HIV-related to provide 
direction to programmes and policies for preserving health 
among adults ageing with HIV.
Implications of all the available evidence
Traditional risk factors contribute greatly to the burden of 
age-related diseases in adults with HIV. Early ART initiation, 
implementing care models that can sustain a focus on 
traditional risk-factor reduction after ART initiation and viral 
suppression, and improving the effectiveness of risk factor 
interventions are essential to preserving health among adults 
with HIV.
For a map of NA-ACCORD sites 
see http://www.naaccord.org
Public Health internal review board approved the present 
study.
Procedures
The protocol for ascertainment and validation of cancer, 
type 1 myocardial infarction, end-stage liver disease, and 
end-stage renal disease (outcomes of interest) within the 
NA-ACCORD has been previously published (appendix 
pp 1–3).17–19 First non-AIDS-defining cancer (which 
excludes cervical cancer, non-Hodgkin lymphoma, and 
Kaposi’s sarcoma) was our cancer outcome of interest; 
non-melanoma skin cancers and precancers were also 
excluded. Only type 1 myocardial infarctions that were 
the result of atherothrombotic coronary events from 
plaque rupture were included; type 2 myocardial infarc-
tions have different causes (eg, hypotension, hypoxia, 
and stimulant-induced spasm resulting in increased 
oxygen demand or decreased supply).
Calendar periods in which validated outcomes were 
actively ascertained (observation window) were defined 
for each outcome and for each cohort. Participants 
entered our nested studies at enrolment into the 
NA-ACCORD, the start of the outcome observation 
window, or Jan 1, 2000, whichever came later. Participants 
were followed up until the latest of: event of interest; 
death; 1 year after the date of the last CD4 cell count or 
HIV RNA measurement; the end of the outcome 
observation window; or Dec 31, 2009, for end-stage liver 
and renal outcomes, Dec 31, 2013, for the myocardial 
infarction outcome, or Dec 31, 2014, for the non-AIDS 
defining cancer outcome. We excluded prevalent cases of 
our events of interest. 
Traditional risk factors were chosen on the basis of 
previously identified r isk f actors f or t he o utcomes o f 
interest and data availability, and included cigarette 
smoking (ever or never), elevated total cholesterol 
(≥240 mg/dL; statin prescription was accounted for 
separately in analyses), hypertension (clinical diagnosis 
and an antihypertensive medication prescription), 
type 2 diabetes (diabetes-specific medication, a diagnosis 
with a diabetes-related medication, or a glycosylated 
haemoglobin ≥6·5%), stage 4 chronic kidney disease 
(estimated glomerular filtration r ate < 30 m L/min 
per 1·73 m² vs ≥30 mL/min per 1·73 m², with the 
Chronic Kidney Disease Epidemiology Collaboration 
equation20). Elevated total cholesterol, hypertension, 
diabetes, and stage 4 chronic kidney disease were time 
varying with the restriction that once an individual met 
the definition, t he c lassification wa s no t re versible.
At-risk alcohol use (ever reporting ≥3 drinks per day or 
≥7 drinks per week for women, or ≥4 drinks/day or 
≥14 drinks/week for men) and body-mass index measure-
ments were available for a subgroup of participants 
enrolled in contributing cohorts that measured these risk 
factors.
We classified h epatitis C  i nfection ( having a  p ositive 
antibody test or detectable RNA, or the presence of 
a hepatitis C genotype test; ever vs never) and hepatitis B 
infection (having a positive surface-antigen test, a positive 
e-antigen test, or a detectable DNA test result; ever vs
never) as preventable and modifiable traditional risk
factors because of their causal relationships with liver
cancer and end-stage liver disease.
Traditional HIV-related risk factors included CD4 cell 
count (categorised using the clinically meaningful 
cutoff for severe immune deficiency threshold of 
<200 cells per µL versus ≥200 cells per µL), HIV viral 
suppression (HIV-1 RNA ≤400 copies per mL), and a 
history of a clinical AIDS-defining illness excluding the 
criteria of a CD4 count of less than 200 cells per µL.21 
CD4 cell count and HIV viral suppression were time 
varying. As is true in clinical care, a history of AIDS was 
also time varying with the restriction that once an 
individual met the definition, the classification was not 
reversible. CD4 counts of less than 200 cells per µL and 
detectable viral loads are modifiable with effective ART, 
and AIDS is preventable with early HIV diagnosis and 
ART initiation. ART prescription was not considered as 
a risk factor because of the associations of ART with 
CD4 cell count, HIV RNA, and clinical AIDS diagnosis. 
Investigations of specific antiretroviral drugs, such as 
abacavir or tenofovir, that would require additional 
adjustment for confounding by indication are outside 
the scope of our study.
Non-modifiable covariates included age, sex (male and 
female), race and ethnicity (white, black, hispanic, and 
other), and HIV-acquisition risk group (men who have 
sex with men, individuals reporting current or previous 
injection drug use, heterosexual, and other) were self-
reported at enrolment into the NA-ACCORD. Although 
current use is a modifiable risk factor, injection drug use 
as the suspected mode of HIV transmission is not 
modifiable.
Statistical analysis
All analyses were done separately for each outcome 
(non-AIDS-defining cancers, myocardial infarction, end-
stage liver disease, and end-stage renal disease), and an 
individual could contribute data to each of the outcome-
specific analyses.
As PAFs incorporate the prevalence of risk factors 
among people with the outcome (estimated as a simple 
proportion) and the risk of the outcome, we estimated 
adjusted hazard ratios (aHR) and 95% CIs with Cox 
proportional hazard models with piecewise constant 
baseline hazard functions. The PAFs approach for disease 
incidence described by Laaksonen22 was used because it 
accommodated time-varying risk factors available from a 
cohort study design. Death would preclude the outcome 
of interest. The Laaksonen approach22 accounted for 
mortality as well as the associations between death and 
the risk factors of interest in the estimation of the PAF. 
Participant follow-up time was divided into periods of 
2 years. Age, sex, race and ethnicity, and injection drug 
See Online for appendix
use status were accounted for in adjusted models that 
produced PAF estimates and 95% CIs. Schoenfeld 
residual global tests and Kolmogorov-type supremum 
tests were used to test the a ssumption of proportional 
hazards for all risk factors of interest.23
A sensitivity analysis was done after removing lung 
cancer from the non-AIDS-defining cancers outcome as it 
was the most common cancer and has a strong relationship 
with smoking. A sensitivity analysis was also done after 
removing elevated total cholesterol from the end-stage 



















<40 years 29 429 (49%) 317 (23%) 13 749 (47%) 63 (18%) 16 641 (48%) 124 (32%) 16 344 (46%) 94 (37%)
40–49 years 20 584 (34%) 550 (39%) 10 217 (35%) 144 (41%) 12 474 (36%) 160 (41%) 13 042 (37%) 101 (40%)
50–59 years 8239 (14%) 390 (28%) 4220 (14%) 106 (31%) 4528 (13%) 80 (21%) 4835 (14%) 41 (16%)
≥60 1843 (3%) 148 (11%) 982 (3%) 34 (10%) 1014 (3%) 23 (6%) 1144 (3%) 19 (7%)
Male 46 330 (77%) 1093 (78%) 23 475 (80%) 298 (86%) 27 354 (79%) 334 (86%) 27 974 (79%) 178 (70%)
Race and ethnicity
White 25 075 (42%) 692 (49%) 13 429 (46%) 193 (56%) 14 560 (42%) 207 (53%) 15 022 (42%) 30 (12%)
Black 21 658 (36%) 534 (38%) 10 831 (37%) 123 (35%) 11 693 (34%) 108 (28%) 11 452 (32%) 205 (80%)
Hispanic 7683 (13%) 111 (8%) 3106 (11%) 20 (6%) 4379 (13%) 43 (11%) 4756 (13%) 12 (5%)
Other 3033 (5%) 44 (3%) 1308 (4%) 10 (3%) 1269 (4%) 7 (2%) 1333 (4%) 1 (0%)
Unknown or missing 2646 (4%) 24 (2%) 494 (2%) 1 (0%) 2756 (8%) 22 (6%) 2802 (8%) 7 (3%)
HIV transmission risk
MSM 31 370 (52%) 742 (53%) 16 103 (55%) 193 (56%) 17 514 (51%) 180 (47%) 17 114 (48%) 67 (26%)
IDU 6885 (11%) 204 (15%) 2971 (10%) 44 (13%) 4231 (12%) 97 (25%) 3912 (11%) 52 (20%)
Heterosexual contact 15 397 (26%) 343 (24%) 7559 (26%) 84 (24%) 9224 (27%) 73 (19%) 9065 (26%) 108 (42%)
Other, unknown, or missing 6443 (11%) 116 (8%) 2535 (9%) 26 (7%) 3688 (11%) 37 (10%) 5274 (15%) 28 (11%)
Traditional Risk Factors
Smoking
Never 13 604 (23%) 236 (17%) 6891 (24%) 55 (16%) 6916 (20%) 57 (15%) 7645 (22%) 41 (16%)
Ever 37 013 (62%) 1106 (79%) 21 884 (75%) 292 (84%) 20 588 (59%) 289 (75%) 20 711 (59%) 182 (71%)
Missing 9478 (16%) 63 (4%) 393 (1%) 0 (0%) 7153 (21%) 41 (11%) 7009 (20%) 32 (13%)
Elevated TC 10 037 (17%) 325 (23%) 7287 (25%) 211 (61%) 7032 (20%) 66 (17%) 6779 (19%) 108 (42%)
Hypertension 5230 (9%) 237 (17%) 2809 (10%) 89 (26%) 2234 (6%) 53 (14%) 2365 (7%) 68 (27%)
Diabetes 1660 (3%) 68 (5%) 766 (3%) 27 (8%) 855 (2%) 20 (5%) 928 (3%) 29 (11%)
Stage 4 CKD 889 (1%) 35 (2%) 610 (2%) 20 (6%) 634 (2%) 26 (7%) 479 (1%) 83 (33%)
Statin Prescription 2260 (4%) 95 (7%) 1449 (5%) 50 (14%) 812 (2%) 11 (3%) 1090 (3%) 16 (6%)
HCV infection 10 379 (17%) 356 (25%) 5392 (18%) 92 (27%) 6700 (19%) 197 (51%) 6189 (18%) 88 (35%)
HBV infection 4814 (8%) 156 (11%) 1766 (6%) 30 (9%) 3535 (10%) 108 (28%) 2225 (6%) 31 (12%)
HIV-related risk factors
Low CD4 count 13 337 (22%) 396 (28%) 7034 (24%) 112 (32%) 8875 (26%) 139 (36%) 8805 (25%) 93 (36%)
Detectable HIV RNA 34 408 (57%) 809 (58%) 16 523 (57%) 184 (53%) 19 862 (57%) 217 (56%) 19 422 (55%) 176 (69%)
Clinical AIDS diagnosis 10 158 (17%) 353 (25%) 6284 (22%) 109 (31%) 7392 (21%) 102 (26%) 7695 (22%) 94 (37%)
ART regimen
Treatment naive 25 216 (42%) 452 (32%) 11 478 (39%) 90 (26%) 14 170 (41%) 96 (25%) 13 065 (37%) 75 (29%)
PI-based ART 12 394 (21%) 406 (29%) 5842 (20%) 114 (33%) 7707 (22%) 117 (30%) 7606 (22%) 51 (20%)
NNRTI-based ART 10 289 (17%) 217 (15%) 5121 (18%) 44 (13%) 5465 (16%) 50 (13%) 6756 (19%) 35 (14%)
Other ART 5591 (9%) 155 (11%) 2402 (8%) 43 (12%) 2858 (8%) 56 (14%) 3278 (9%) 35 (14%)
Treatment experienced but 
not prescribed ART
6558 (11%) 174 (12%) 4325 (15%) 56 (16%) 4457 (13%) 68 (18%) 4660 (13%) 59 (23%)
Values are n (%). NADC=non-AIDS-defining cancers. MI=myocardial infarction. ESLD=end-stage liver disease. ESRD=end-stage renal disease. MSM=men who have sex with men. IDU=history of injection drug 
use. TC=total cholesterol. CKD=chnic kidney disease. HCV=hepatitis C virus. HBV=hepatitis B virus. ART=antiretroviral therapy. PI=protease inhibitor. NNRTI=non-nucleoside reverse transcriptase inhibitor. 
Table: Participant characteristics at study entry, by non-AIDS-defining cancers (n=61 500), myocardial infarction (n=29 515), end-stage liver disease (n=35 044), and end-stage renal 
disease (n=35 620) diagnoses 
renal disease outcome because of the relationship of renal 
impairment and dyslipidaemia.24 Subgroup analyses were 
done for the myocardial infarction outcome among people 
with body mass-index data and for the end-stage liver 
disease outcome among people with at-risk alcohol use 
data; cohorts that did not contribute data on these risk 
factors were excluded from the subgroup analyses. All 
analyses were done using SAS version 9·3; statistical 
interpretation was guided by a p value of less than 0·05 
and PAF 95% CIs that do not cross 0%.
Role of the funding source
The funders of the study had no role in the study design, 
data collection, data analysis, data interpretation, or 
writing of the manuscript. The content is solely the 
responsibility of the authors and does not necessarily 
represent the official views of the funders. YJ had full 
access to all the data in the study and KNA had final 
responsibility for the decision to submit for publication.
Results
Among 72 854 NA-ACCORD participants from 21 cohorts 
with validated non-AIDS-defining cancer outcomes, 
9202 were excluded as prevalent cases or not contributing 
observation time during the study period (Jan 1, 2000, to 
Dec 31, 2014) and 2152 were excluded for having an 
AIDS-defining cancer as their first cancer, resulting 
in 61 500 participants, of whom 1405 (2%) had a 
validated non-AIDS defining cancer diagnosis. Among 
34 708 participants from seven cohorts with validated 
myocardial infarction diagnoses, 5193 were excluded as 
prevalent cases or not contributing observation time 
during the study period (Jan 1, 2000, to Dec 31, 2013), 
resulting in 29 515 participants, of whom 347 (1%) had a 
validated myocardial infarction diagnosis. Among 
42 609 participants from 12 cohorts with validated end-
stage liver disease diagnoses, 7025 were excluded as 
prevalent cases or not contributing observation time 






















































































Sensitivity analysis, excluding lung cancer
24%
14%
3% 3% 2% 1% 1% 1% 3% 3% 0% 1%
Figure 1: Population attributable fractions for traditional and HIV related factors for non-AIDS-defining cancer, overall (n=61 500) and excluding lung cancer 
(n=61 235)
Bars indicate 95% CI. The calculation of the population attributable fraction allows for time-varying risk factors. 265 participants with lung cancer were excluded in the 
sensitivity analysis; 230 with lung cancer as a first cancer diagnosis, nine with a lung cancer diagnosis after another cancer diagnosis, and 26 participants who had a lung 
cancer diagnosis reported after the close of the observation window. Hence, there were 61 235 participants for the sensitivity analysis excluding lung cancer, of whom 
1166 had a cancer diagnosis while under observation and 60 069 did not. Below the plot, prevalence is the prevalence of the risk factor among those with the outcome at 
study entry; aHRs were adjusted for age, sex, race and ethnicity, history of injection drug use, and all the risk factors shown in the figure. Bold indicates significant 
estimates. aHR=adjusted hazard ratio. HBV=hepatitis B virus infection. HCV=heptitis C virus infection.
resulting in 35 044 participants, of whom 387 (1%) had 
a validated end-stage liver disease diagnosis. Among 
43 961 participants from 12 cohorts with validated end-
stage renal disease diagnoses, 8341 were excluded as 
prevalent cases or not contributing observation time 
during the study period (Jan 1, 2000, to Dec 31, 2009), 
resulting in 35 620 participants, of whom 255 (1%) had a 
validated end-stage liver disease diagnosis (appendix p 4).
Median follow-up time was similar across the 
four outcomes: 3·7 years (IQR 1·4–7·7) for non-AIDS-
defining cancer, 3·5 years (1·5–6·9) for myocardial 
infarction, 3·1 years (1·3–6·2) for end-stage liver disease, 
and 3·3 years (1·4–5·7) for end-stage renal disease 
(appendix, p 5). Of the 1405 non-AIDS-defining cancers 
observed, 230 (16%) were lung, 225 (16%) were anal, 
167 (12%) were prostate, 96 (7%) were Hodgkin lymph-
oma, 90 (6%) were liver, 83 (6%) were oral cavity and 
pharynx, 82 (6%) were breast, 69 (5%) were melanoma, 
and 65 (5%) were colon and rectum cancers. Each of the 
other type-specific cancers accounted for less than 5% of 
the 1405 cancer diagnoses (appendix p 6).
For all four incident outcomes, there was a greater 
proportion of participants with a smoking history, 
hepatitis C and B infection, low CD4 cell count 
(<200 cells per µL), and a history of a clinical AIDS 
diagnosis among individuals with an incident outcome 
than among those who did not develop the outcomes 
(table). The prevalence of elevated total cholesterol, 
hypertension, diabetes, and stage 4 chronic kidney 
disease was higher among individuals with an incident 
myocardial infarction than among those without. The 
proportion of individuals with a detectable viral load 
was higher among those with a diagnosis of end-stage 
renal disease than among those without an incident 
diagnosis, but the proportion of individuals with 
detectable HIV RNA was similar by incident diagnosis 
status for all other outcomes. Individuals with an 



















































































































































Figure 2: Population attributable fractions for traditional and HIV-related risk factors for myocardial infarction, overall (n=29 515) and among those with BMI 
data (n=16 687)
Bars indicate 95% CI. The calculation of the population attributable fraction allows for time-varying risk factors. The subgroup analysis was restricted to the 
16 687 (57%) participants for whom BMI data were available; 227 of these participants had a type 1 myocardial infarction diagnosis while under observation and 
16 460 did not. Below the plot, prevalence is the prevalence of the risk factor among those with the outcome at study entry; aHRs were adjusted for age, sex, 
race and ethnicity, history of injection drug use, and all the risk factors shown in the figure. Bold indicates significant estimates. aHR=adjusted hazard ratio. 
BMI=body-mass index. HBV=hepatitis B virus infection. HCV=hepatitis C virus infection.
greater proportions of elevated total cholesterol, 
hypertension, and diabetes than those who did not 
develop this outcome.
In addition to the prevalence of the risk factor, PAFs are 
influenced by the risk of the outcome associated with 
each preventable or modifiable risk factor. We calculated 
the aHRs allowing some risk factors (ie, elevated total 
cholesterol, hypertension, type 2 diabetes, stage 4 chronic 
kidney disease, low CD4 cell count, detectable HIV RNA, 
history of AIDS-defining illness) to vary with time and 
adjusting for age (time varying), sex, race and ethnicity, 
and a history of injection drug use.
For non-AIDS-defining c ancer, t he p reventable o r 
modifiable r isk f actors w ith s ignificant as sociations 
were smoking, low CD4 cell count, detectable HIV 
RNA, a history of clinical AIDS diagnosis, and 
hepatitis B infection (figure 1). In a sensitivity analysis 
excluding individuals with lung cancer diagnoses, the 
effect of smoking attenuated, but there was still an 
association between smoking and non-AIDS-defining 
cancer (aHR 1·36, 95% CI 1·15–1·60).
Smoking, elevated total cholesterol, hypertension, 
stage 4 chronic kidney disease, a low CD4 cell count, 
detectable HIV RNA, and hepatitis C infection were 
associated with myocardial infarction (figure 2). In a 
subgroup analysis restricted to 16 687 individuals (57%) 
with available body mass-index measurements, there 
was no evidence of an association of obesity with 
myocardial infarction in the adjusted model, whereas 
the associations of elevated total cholesterol, diabetes, 
stage 4 chronic kidney disease, low CD4 cell count, and 
hepatitis C infection with this outcome strengthened; 
all other associations attenuated.
For end-stage liver disease, low CD4 cell count, 
detectable HIV RNA, a history of a clinical AIDS diagnosis, 
and hepatitis infection (B or C) were associated with the 
outcome (figure 3). In a subgroup analysis restricted to 
12 158 participants (35%) with known at-risk alcohol 
Figure 3: Population attributable fractions for traditional and HIV-related risk factors for ESLD, overall (n=35 044) and among those with at-risk alcohol use 
data (n=12 158)
Bars indicate 95% CI. The calculation of the population attributable fraction allows for time-varying risk factors. The subgroup analysis was restricted to the 
12 158 (35%) participants for whom at-risk alcohol-use data were available; 176 of these participants had ESLD diagnosis while under observation and 11 982 did not. 
Below the plot, prevalence is the prevalence of the risk factor among those with the outcome at study entry; aHRs were adjusted for age, sex, race and ethnicity, 
history of injection drug use, and all the risk factors shown in the figure. Bold indicates significant estimates. aHR=adjusted hazard ratio. BMI=body-mass index. 
























































































































status, at-risk alcohol consumption was associated with 
end-stage liver disease. The inclusion of at-risk alcohol 
consumption in the model diminished the effects of 
smoking and a history of a clinical AIDS diagnosis, 
strengthened the association with low CD4 cell count, and 
attenuated the effects of the remaining risk factors 
(figure 3).
For end-stage renal disease, elevated total cholesterol, 
hypertension, diabetes, low CD4 cell count, detectable 
HIV RNA, and a history of clinical AIDS diagnosis 
showed significant associations (figure 4). 
Schoenfeld residual global test approach and the 
Kolmogorov-type supremum test of the proportional 
hazards assumption showed proportionality for all risk 
factors presented (data not shown).
The PAF for smoking was substantial for non-AIDS-
defining cancer (24%, 95% CI 13–35) and myocardial 
infarction (37%, 7–66), but was not for end-stage liver or 
renal disease. For the non-AIDS-defining cancers 
outcome, the PAF for smoking was greater the PAFs for 
HIV-related risk factors and persisted after excluding lung 
cancer cases.
For myocardial infarction, PAFs were higher for 
elevated total cholesterol (44%, 95% CI 30–58) and 
hypertension (42%, 28–56) than for smoking (37%, 7–66); 
these were all larger than those for HIV-related risk 
factors. In the subgroup analysis among persons with 
body mass-index measure ments, after adjustment for 
body-mass index, the magnitude of the PAFs for 
traditional risk factors did not meaningfully change 
(however, the PAF for smoking was no longer significant), 
and the magnitude of the PAFs for the low CD4 cell 
count and hepatitis C infection increased slightly (and 
the PAF for hepatitis C infection became significant).
Hepatitis C infection had the highest PAF (30%, 
95% CI 21–39) for end-stage liver disease, followed by 
low CD4 cell count (19%, 12–26) and hepatitis B infection 
(16%, 11–21). In the subgroup analysis among individuals 
with at-risk alcohol consumption measurements, the 
PAF for at-risk alcohol consumption (35%, 9–60) was 
greater than that for hepatitis C infection (33%, 17–48).
Hypertension had the highest PAF for end-stage renal 
disease (39%, 95% CI 26–51). PAFs were similar for 
elevated total cholesterol (22%, 13–31) and detectable 
HIV RNA (19%, 6–31), whereas we estimated lower PAFs 
for low CD4 cell count (13%, 4–21) and diabetes (6%, 
1–10). We found no significant contribution for smoking, 
a history of a clinical AIDS diagnosis, or hepatitis C 
infection to the increased burden of end-stage renal 
disease. In the sensitivity analysis, the PAFs for the 
remaining risk factors did not vary substantially after 
removal of total elevated cholesterol (data not shown).
PAFs grouped by risk factors (as opposed to oucomes) 
are shown in the appendix (pp 7–8).
Figure 4: Population attributable fractions for traditional and HIV-related risk factors for ESRD (n=35 620)
Bars indicate 95% CI. The calculation of the population attributable fraction allows for time-varying risk factors. Below the plot, prevalence is the prevalence of the 
risk factor among those with the outcome at study entry; aHRs were adjusted for age, sex, race and ethnicity, history of injection drug use, and all the risk factors 
shown in the figure. This analysis of population attributable factors for factors associated with ESRD did not include accounting for stages of chronic kidney disease. 






















































































In the population of adults with HIV who were 
successfully linked to care, we found that traditional risk 
factors, including smoking, elevated total cholesterol, 
hypertension, and chronic hepatitis C infection
accounted for a larger share of the non-AIDS-defining 
cancer, myocardial infarction, end-stage liver disease, 
and end-stage renal disease incident outcomes than did 
HIV-related risk factors. The PAF approach accounts for 
not only the risk of the outcome associated with the risk 
factor, but also the prevalence of the risk factor among 
individuals with the outcome. A high PAF can result 
from a risk factor with a weak or moderately strong 
association with the outcome but with a high prevalence; 
conversely, a low PAF can result from a strong risk factor 
with a low prevalence. With both pieces of information, 
the evidence from our study is clear: to avoid sizeable 
proportions of non-AIDS-defining c ancers, m yocardial 
infarction, end-stage liver disease, and end-stage renal 
disease, the continued focus on maintaining HIV viral 
suppression after ART initiation must be balanced with 
screening for traditional risk factors, effective inter-
ventions to reduce the burden of traditional risk factors, 
and a sustainable model of care with the capacity to 
provide traditional risk factor interventions over the 
decades of life with HIV.
Many interventions used to reduce traditional risk 
factor burden in adults with HIV were developed in the 
general population and might need modifications to 
improve effectiveness in adults with HIV. For example, 
smoking cessation programmes with reduced financial 
barriers to nicotine replacement therapy and increased 
social support could improve the scarce success of 
smoking cessation programmes, a challenge that plagues 
both adults with and without HIV, but has a greater effect 
on adults with HIV because of the two-times higher 
prevalence of smoking in this population than in the 
general population.25–28 Similarly, interventions for 
alcohol use reduction and for screening and treating 
dyslipidaemia, hypertension, and diabetes might need 
tailoring to meet the needs of adults with HIV and to 
have a substantial effect. Beyond the individual-level 
interventions, structural and policy interventions on 
traditional risk factors could have large effects a mong 
adults with HIV, who carry an increased burden of 
traditional risk factors. For example, a 2018 simulation 
study29 suggested that lowering nicotine content in 
cigarettes could result in a 15·6% decrease in smoking 
prevalence (from 12·8% to 10·8% in the overall US 
population) in the first year of the policy. The benefit of 
this structural inter vention would not be limited to 
reducing smoking prevalence among adults with HIV 
but would also benefit the general population. The 
evaluation of the effectiveness of modified interventions 
and cost analyses for effective interventions are needed.
Individual-level traditional risk factor interventions 
must be accessible to adults with HIV; herein lie 
substantial challenges. Driven by the increased life 
expectancy of adults with HIV initiating ART at early 
stages of disease, the size of the population of adults with 
HIV will continue to increase within the context of 
current and projected shortages of HIV care providers in 
some settings, such as the USA.30 There is a need for 
sustainable models that have the capacity for risk factor 
interventions (many of which might need to be offered 
numerous times over decades of life with HIV) and 
management of complex health-care needs with multi-
disciplinary teams, when non-communicable diseases 
are not avoided. General-practitioner, nurse-practitioner, 
and care-coordinator models that are common in other 
medically complex settings (such as oncology and 
transplantation) should be evaluated for implementation 
as the primary medical home for adults with HIV. More 
formal adoption of geriatric-medicine principles and 
patient-centred care approaches in HIV-care models 
might be particularly beneficial.31–33
We caution against common misinterpretation of PAFs, 
which should be interpreted as the “proportion of disease 
cases over a specified time that would be prevented 
following elimination of the exposure, assuming the 
exposure is causal”.34 The relationhips between the risk 
factors included in this investigation and each outcome 
range from meeting Bradford Hill’s causal criteria 
(eg, smoking and non-AIDS defining cancers) to being 
incompletely verified as causal (eg, HIV RNA, which is 
a time-dependent surrogate for inflammation from 
uncontrolled viraemia).35 Although the interpretation of 
the PAF is one of prevention of the risk factor (ie, the 
proportion of the outcome that could be avoided if all 
members of the study population never started smoking), 
modification of these risk factors might be a more 
achievable approach than prevention. It is commonly 
assumed that the proportion of outcomes avoided by 
modifying the risk factor (eg, smoking cessation) is likely 
to be similar to that of preventing the risk factor 
(ie, smoking prevention), although it might be smaller 
because the risk of developing the outcome does not 
immediately drop to that of the unexposed group (ie, non-
smokers) at the time of modification (ie, cessation).36 
However, we did not directly assess the effect of 
modification.
We also caution against inappropriately summing the 
single risk factor PAFs in an attempt to derive the total 
fraction of disease risk attributable to all of the factors 
because the few conditions under which this approach is 
valid do not apply to this study.37
Our approach might have underestimated PAFs for 
many of the traditional risk factors. For example, the 
proportion of outcomes that would be avoided if smoking 
were prevented was probably underestimated because 
current and former smokers were combined in the 
category of participants who have ever smoked, thus 
increasing the prevalence of this exposure but diluting 
the strength of the associations between smoking and 
the outcomes. Because hypertension was categorised as 
diagnosed and treated hypertension, the prevalence was 
probably underestimated and the associations between 
hypertension and the outcomes might have been diluted 
(systolic and diastolic blood pressure measurements 
were not available for this study). This could also be the 
case for diabetes, as the individuals with undiagnosed 
diabetes and no glycated haemoglobin A1c test did not 
meet the criteria to be classified as having diabetes, thus 
reducing the prevalence of diabetes and potentially 
diluting the association between diabetes and the 
outcomes. The PAF for hepatitis C infection might also 
have been affected by the way we defined having a 
positive antibody, which included individuals who 
resolved their hepatitis C infection, and thus might have 
caused an overestimation of the prevalence of hepatitis C 
but probably diluted the associations with the outcomes. 
Direct acting antivirals for hepatitis C were not licensed 
until the last year of our study.
Although we examined consistently measured risk 
factors across four validated non-communicable disease 
events, a limitation of our study is the possibility that 
additional preventable or modifiable causal risk factors 
were not considered, such as specific antiretroviral drugs 
and regimens (and associated metabolic effects), diet, 
physical activity, and proteinuria. To estimate the PAF for 
specific antiretroviral drugs and regimens, methods are 
needed to account for confounding by indication (perhaps 
by incorporating weights into the approach) so that specific 
antiretroviral drugs and regimens do not show spuriously 
protective outcomes. Furthermore, investigations into 
causal interactions between specific antiretroviral drugs or 
regimens and risk factors are needed to incorporate the 
complexities of HIV treatments when estimating the 
burden of non-communicable-disease outcomes that 
could be avoided. Risk factors that are not preventable or 
modifiable (such as the estimated 66% of cancer-driving 
mutations that are caused by random DNA replication 
errors in healthy, dividing cells) might also have been at 
play but unaccounted for.38 Although we cannot weigh the 
benefit of intervention upon these omitted risk factors, we 
believe we have included the most relevant known risk 
factors for each outcome. Additionally, current smoking 
was not included as a possible category of smoking, which 
is an important limitation. Given the high prevalence of 
smoking and the low cessation rates among adults with 
HIV, we suspect the PAF for ever smoking presented here 
is between the unknown PAFs for current and former 
smoking.27,28 Finally, our findings cannot be interpreted as 
the effect of HIV itself on these outcomes because all 
patients in this study were infected with HIV; the goal was 
to assess the population-level effect of traditional and HIV-
related risk factors on non-AIDS-defining cancers, 
myocardial infarction, end-stage liver disease, and end-
stage renal disease among adults ageing with HIV.
In summary, preventing the high burden of non-
communicable diseases among adults ageing with HIV 
will require prioritisation of interventions. Our findings 
show that individual and structural or policy-level 
interventions on traditional risk factors in the context of 
antiretroviral-induced chronic viral suppression could 
prevent a substantial proportion of non-communicable 
diseases. Interventions to prevent and address smoking, 
elevated total cholesterol, and hypertension are par-
ticularly important for reducing non-AIDS-defining 
cancers, myocardial infarction, and end-stage renal 
disease out comes. Hepatitis C infection and at-risk 
alcohol use prevention and treatment are crucial to 
reducing the burden of end-stage liver disease. Modifi-
cations to individual-level interventions and models of 
HIV care, and the implementation of structural and 
policy-level interventions that focus on prevention and 
modification of traditional risk factors are necessary to 
avoid non-communicable diseases and preserve health 
among successfully antiretroviral-treated adults ageing 
with HIV.
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